Bird, R. E. et al. Single-chain antigen-binding proteins. Science 242, 423–426 (1988).

CAS  PubMed  Article  PubMed Central  Google Scholar 

June, C. H., Ledbetter, J. A., Gillespie, M. M., Lindsten, T. & Thompson, C. B. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell Biol. 7, 4472–4481 (1987).

CAS  PubMed  PubMed Central  Google Scholar 

Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279–286 (2003).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Mullis, K. B. The unusual origin of the polymerase chain reaction. Sci. Am. 262, 56–65 (1990).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20–e22 (2006).

PubMed  Article  PubMed Central  Google Scholar 

Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720–724 (1993).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Sadelain, M.Chimeric antigen receptors: a paradigm shift in immunotherapy. Ann. Rev. Cancer Biol. 1, 447–466 (2017).

Article  Google Scholar 

Filley, A. C., Henriquez, M. & Dey, M.CART immunotherapy: development, success, and translation to malignant gliomas and other solid tumors.Front. Oncol. 8, 453 (2018).

PubMed  PubMed Central  Article  Google Scholar 

Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453–1464 (2009).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106, 3360–3365 (2009).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zhao, Y. et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563–5574 (2009).

CAS  PubMed  Article  Google Scholar 

Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822–1826 (2011).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Friedmann-Morvinski, D., Bendavid, A., Waks, T., Schindler, D. & Eshhar, Z. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105, 3087–3093 (2005).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Brocker, T. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96, 1999–2001 (2000).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Mitsuyasu, R. T. et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects. Blood 96, 785–793 (2000).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra153 (2012).

Article  Google Scholar 

Uckun, F. et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71, 13–29 (1988).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Ishiura, N. et al. Differential phosphorylation of functional tyrosines in CD19 modulates B‐lymphocyte activation. Eur. J. Immunol. 40, 1192–1204 (2010).

CAS  PubMed  Article  PubMed Central  Google Scholar 

LeBien, T. W. & Tedder, T. F. B lymphocytes: how they develop and function. Blood 112, 1570–1580 (2008).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102 (2010).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817–4828 (2011).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Grupp, S. A. et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Maude, S. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540–549 (2015).

CAS  PubMed  Article  Google Scholar 

Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).

PubMed  PubMed Central  Article  Google Scholar 

Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).

CAS  PubMed  Article  Google Scholar 

Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123–2138 (2016).

PubMed  PubMed Central  Article  Google Scholar 

Turtle, C. J. et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 8, 355ra116 (2016).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545–2554 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35, 1803–1813 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Turtle, C. J. et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J. Clin. Oncol. 35, 3010–3020 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Locke, F. L. et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25, 285–295 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Melenhorst, J. J. et al. Long-term remission of CLL sustained by pauciclonal anti-CD19 chimeric antigen receptor T (CTL019) cell clones. Blood 132 (Suppl. 1), 699 (2018).

Article